H.C. Wainwright analyst Yi Chen raised the firm’s price target on Harrow (HROW) to $64 from $60 and keeps a Buy rating on the shares. The firm updated the company’s model post the Q2 report.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HROW:
- Harrow Health Reports Strong Q2 2025 Financial Results
- Harrow Health’s Strong Operational Efficiency and Strategic Partnerships Justify Buy Rating
- HROW Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Harrow Health’s Strategic Acquisition and Market Positioning Justify Buy Rating
- Harrow enters commercialization agreement with Samsung Bioepis for biosimilars